HC Wainwright & Co. Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $30
HC Wainwright & Co. Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $30
HC Wainwright & Co.買入評級Mineralys Therapeutics,宣佈30美元的目標價。
HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $30.
HC Wainwright & Co.分析師Matthew Caufield對Mineralys Therapeutics (納斯達克股票代碼:MLYS)進行買入評級,目標價爲30美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。